Cell Therapy of Cerebral Palsy

Селедцов, В. И.; Kafanova, M. Yu.; Rabinovich, S. S.; Повещенко, О. В.; Kashchenko, E. A.; Fel’de, M. A.; Самарин, Д. М.; Селедцова, Г. В.; Va, Kozlov

doi:10.1007/s10517-005-0330-2

Cited by 8 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our clinical observations, most patients were excited and had difficulty in falling asleep within the first 1–3 days following transplantation, which we attributed to the stimulating effects of neurotrophic factors released by NPCs. Some patients showed improvements within a few days after the surgery, which was consistent with the observations of Chen et al (5) and Seledtsov et al (36) after treating children with CP using olfactory ensheathing cells and fetal brain cells. They reported that most patients had abatement in manifestations within a few days after therapy.…”

Section: Discussionsupporting

confidence: 89%

“…In contrast, the effects of cell transplantation on patients with stroke, Parkinson's disease, and Huntington's disease were apparent much later than in this study (18,22), probably due to the different environments in the brain of the various subjects investigated. The subjects investigated in the present study and in the study by Seledtsov et al (36) were children of nonprogressive brain injury with permanent damage. Because developing brains have stronger plasticity and capability than adult ones, these quick effects were probably due to endogenous neural mechanism that was quickly activated by neurotrophic factors, such as glial cell-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), and neural growth factor (NGF) released by grafted NPCs (10,26,43).…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Effects of Neural Progenitor Cell Transplantation in Children with Severe Cerebral Palsy

Zuo

Liu

et al. 2012

Cell Transplant

View full text Add to dashboard Cite

One endpoint of clinical islet cell transplantation for type 1 diabetic patients is the elimination or reduction of hypoglycemia. We previously developed a simple tool to evaluate islet graft function: the secretory unit of islet transplant objects (SUITO) index. The aim of this study is to clarify the association between the SUITO index and hypoglycemic episodes. Data from 310 clinical evaluations of 11 islet recipients were included in this study. Fasting plasma C-peptide and glucose levels were measured at every evaluation. The SUITO index was calculated according to the following formula: 1500 × C-peptide level (ng/ml)/[blood glucose level (mg/dl) - 63]. The number of hypoglycemic events (<3.8 mmol/L) and severe hypoglycemic events (<2.2 mmol/L or hypoglycemic unawareness) was assessed on the basis of interviews and self-monitoring of blood glucose (SMBG). Receiver operating characteristic (ROC) analysis was performed to determine the cut-off values of the SUITO index for hypoglycemic events. Based on the ROC study, follow-up data after transplantations were divided into the following three groups: low-SUITO (SUITO index <10, n = 91), middle-SUITO (10 ≤SUITO index <26, n = 83), high-SUITO (SUITO index ≤26, n = 125). The frequency of total hypoglycemia in the high-SUITO group was significantly decreased when compared to the other groups (value with Kruskal-Wallis test p < 0.001). The frequency of total severe hypoglycemia was significantly decreased in the low-SUITO group compared to pretransplant status and further decreased in the middle- and high-SUITO group. Spearman correlation coefficients were -0.663 (p < 0.001) between the number of total hypoglycemic events per one month and the SUITO index and -0.521 (p < 0.001) between that of severe events and the SUITO index. The SUITO index could predict the severity of hypoglycemic episodes in type 1 diabetic patients who received islet cell transplantations.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 76%

Effects of Neural Progenitor Cell Transplantation in Children with Severe Cerebral Palsy

Zuo

Liu

et al. 2012

Cell Transplant

View full text Add to dashboard Cite

show abstract

“…Administration of autologous bone marrow-derived stem cells in patients with subacute and chronic spinal cord injuries has resulted in improvements like changes in ASIA scale as well as electrophysiological changes (6,12,19). In case of cerebral palsy, published data have revealed that cell transplantation in patients suffering from cerebral palsy is found to be safe and showed apparent neurological improvements (10,15,16). For muscular dystrophy, trials have been conducted for transplantation of myoblast cells, mesenchymal stem cells, and umbilical cord stromal cells, proving cell transplantation to be safe and efficacious (18,22).…”

Section: Discussionmentioning

confidence: 99%

Administration of Autologous Bone Marrow-Derived Mononuclear Cells in Children with Incurable Neurological Disorders and Injury is Safe and Improves their Quality of Life

et al. 2012

View full text Add to dashboard Cite

Neurological disorders such as muscular dystrophy, cerebral palsy, and injury to the brain and spine currently have no known definitive treatments or cures. A study was carried out on 71 children suffering from such incurable neurological disorders and injury. They were intrathecally and intramuscularly administered autologous bone marrow-derived mononuclear cells. Assessment after transplantation showed neurological improvements in muscle power and a shift on assessment scales such as FIM and Brooke and Vignos scale. Further, imaging and electrophysiological studies also showed significant changes in selective cases. On an average follow-up of 15 ± 1 months, overall 97% muscular dystrophy cases showed subjective and functional improvement, with 2 of them also showing changes on MRI and 3 on EMG. One hundred percent of the spinal cord injury cases showed improvement with respect to muscle strength, urine control, spasticity, etc. Eighty-five percent of cases of cerebral palsy cases showed improvements, out of which 75% reported improvement in muscle tone and 50% in speech among other symptoms. Eighty-eight percent of cases of other incurable neurological disorders such as autism, Retts Syndrome, giant axonal neuropathy, etc., also showed improvement. No significant adverse events were noted. The results show that this treatment is safe, efficacious, and also improves the quality of life of children with incurable neurological disorders and injury.

show abstract

“…Data suggest that cell therapy is a safe method and can be effectively used for stroke (308), acute brain injury (346,347), and cerebral palsy (345). In addition, neurological function has been restored after autologous neural stem cell transplantation in patients with brain trauma (428).…”

Section: Clinical Studies Of Cell-based Neurorestoratology In Cns Dismentioning

confidence: 99%

Cell Therapy from Bench to Bedside Translation in CNS Neurorestoratology Era

2010

View full text Add to dashboard Cite

Recent advances in cell biology, neural injury and repair, and the progress towards development of neurorestorative interventions are the basis for increased optimism. Based on the complexity of the processes of demyelination and remyelination, degeneration and regeneration, damage and repair, functional loss and recovery, it would be expected that effective therapeutic approaches will require a combination of strategies encompassing neuroplasticity, immunomodulation, neuroprotection, neurorepair, neuroreplacement, and neuromodulation. Cell-based restorative treatment has become a new trend, and increasing data worldwide have strongly proven that it has a pivotal therapeutic value in CNS disease. Moreover, functional neurorestoration has been achieved to a certain extent in the CNS clinically. Up to now, the cells successfully used in preclinical experiments and/or clinical trial/treatment include fetal/embryonic brain and spinal cord tissue, stem cells (embryonic stem cells, neural stem/progenitor cells, hematopoietic stem cells, adipose-derived adult stem/precursor cells, skin-derived precursor, induced pluripotent stem cells), glial cells (Schwann cells, oligodendrocyte, olfactory ensheathing cells, astrocytes, microglia, tanycytes), neuronal cells (various phenotypic neurons and Purkinje cells), mesenchymal stromal cells originating from bone marrow, umbilical cord, and umbilical cord blood, epithelial cells derived from the layer of retina and amnion, menstrual bloodderived stem cells, Sertoli cells, and active macrophages, etc. Proof-of-concept indicates that we have now entered a new era in neurorestoratology.

show abstract

Cell Therapy of Cerebral Palsy

Cited by 8 publications

References 5 publications

Effects of Neural Progenitor Cell Transplantation in Children with Severe Cerebral Palsy

Effects of Neural Progenitor Cell Transplantation in Children with Severe Cerebral Palsy

Administration of Autologous Bone Marrow-Derived Mononuclear Cells in Children with Incurable Neurological Disorders and Injury is Safe and Improves their Quality of Life

Cell Therapy from Bench to Bedside Translation in CNS Neurorestoratology Era

Contact Info

Product

Resources

About